They concluded that future research should focus on studying the role of CLCF1 and related molecules in the etiology of recurrent FSGS as well as consider the application of JAK2 and STAT3 inhibitors in the treatment of FSGS36. This evidence concerns the gene CLCF1 and focal segmental glomerulosclerosis.